Bozzi Fabio, Mogavero Angela, Varinelli Luca, Belfiore Antonino, Manenti Giacomo, Caccia Claudio, Volpi Chiara C, Beznoussenko Galina V, Milione Massimo, Leoni Valerio, Gloghini Annunziata, Mironov Alexandre A, Leo Ermanno, Pilotti Silvana, Pierotti Marco A, Bongarzone Italia, Gariboldi Manuela
Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, Milan, 20133, Italy.
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Amadeo 42, Milan, 20133, Italy.
J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.
Strategies aimed at obtaining a complete cytoreduction are needed to improve long-term survival for patients with colorectal cancer peritoneal carcinomatosis (CRC-pc).
We established organoid models from peritoneal metastases of two naïve CRC patients. A standard paraffin inclusion was conducted to compare their 3D structure and immunohistochemical profile with that of the corresponding surgical samples. RNA expression levels of the CRC stem cell marker LGR5 was measured by in situ hybridization. The secretome of organoids was profiled by mass spectrometry. Energy homeostasis of organoids was interfered with 4-IPP and metformin. Biochemical and metabolic changes after drug treatments were investigated by western blot and mass spectrometry. Mitochondria impairment was evaluated by electron microscopy and mitotraker staining.
The two organoids recapitulated their corresponding clinical samples in terms of 3D structure and immmunoistochemical profile and were positive for the cancer stem cells marker LGR5. Proteomic analyses of organoids highlighted their strong dependence on energy producing pathways, which suggest that their targeting could be an effective therapeutic approach. To test this hypothesis, we treated organoids with two drugs that target metabolism acting on AMP-activated protein kinase (AMPK), the main regulator of cellular energy homeostasis, which may act as metabolic tumour suppressor in CRC. Organoids were treated with 4-IPP, an inhibitor of MIF/CD74 signalling axis which activates AMPK function, or metformin that inhibits mitochondrial respiratory chain complex I. As a new finding we observed that treatment with 4-IPP downregulated AMPK signalling activity, reduced AKT phosphorylation and activated a JNK-mediated stress-signalling response, thus generating mitochondrial impairment and cell death. Metformin treatment enhanced AMPK activation, decreasing the activity of the anabolic factors ribosomal protein S6 and p4EBP-1 and inducing mitochondrial depolarization.
We provide evidence that the modulation of AMPK activity may be a strategy for targeting metabolism of CRC-pc organoids.
需要采取旨在实现完全细胞减灭的策略,以提高结直肠癌腹膜转移(CRC-pc)患者的长期生存率。
我们从两名未经治疗的CRC患者的腹膜转移灶建立了类器官模型。进行标准石蜡包埋,以将其三维结构和免疫组化特征与相应的手术样本进行比较。通过原位杂交测量CRC干细胞标志物LGR5的RNA表达水平。通过质谱分析类器官的分泌组。用4-IPP和二甲双胍干扰类器官的能量稳态。通过蛋白质免疫印迹和质谱研究药物处理后的生化和代谢变化。通过电子显微镜和线粒体示踪剂染色评估线粒体损伤。
这两个类器官在三维结构和免疫组化特征方面重现了其相应的临床样本,并且对癌症干细胞标志物LGR5呈阳性。类器官的蛋白质组学分析突出了它们对能量产生途径的强烈依赖性,这表明靶向这些途径可能是一种有效的治疗方法。为了验证这一假设,我们用两种作用于AMP激活蛋白激酶(AMPK)的靶向代谢药物处理类器官,AMPK是细胞能量稳态的主要调节因子,在CRC中可能作为代谢肿瘤抑制因子发挥作用。用4-IPP(一种激活AMPK功能的MIF/CD74信号轴抑制剂)或抑制线粒体呼吸链复合体I的二甲双胍处理类器官。作为一项新发现,我们观察到用4-IPP处理会下调AMPK信号活性,降低AKT磷酸化并激活JNK介导的应激信号反应,从而导致线粒体损伤和细胞死亡。二甲双胍处理增强了AMPK激活,降低了合成代谢因子核糖体蛋白S6和p4EBP-1的活性,并诱导线粒体去极化。
我们提供的证据表明,调节AMPK活性可能是靶向CRC-pc类器官代谢的一种策略。